| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of ENHERTU® (fam-trastuzumab deruxtecan-nxki) in HER2-positive early breast cancer
TROPION-Breast02 data will demonstrate potential of DATROWAY® (datopotamab deruxtecan-dlnk) in metastatic triple-negative breast cancer, most aggressive subtype
POTOMAC disease-free survival and MATTERHORN survival results will showcase benefit of IMFINZI® (durvalumab) in early bladder and gastric cancers
AstraZeneca advances its ambition to redefine cancer care with new data across its diverse, industry-leading portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, October 17-21, 2025.
More than 95 abstracts will feature nine approved and nine potential new medicines from the Company including two abstracts featured in a late-breaking Presidential Symposium and 26 oral presentations.
Posted In: AZN
